Enanta Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Enanta Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 15% to $67,635,000. The net income raised on -$116,045,000 and profit margin reached -172%. Total operating expenses were $189,326,000.
Profit Margin
| 2015 | 160.88M | 78.99M | 49.1% |
|---|---|---|---|
| 2016 | 88.26M | 21.66M | 24.55% |
| 2017 | 102.81M | 17.71M | 17.23% |
| 2018 | 206.62M | 71.95M | 34.82% |
| 2019 | 205.19M | 46.38M | 22.6% |
| 2020 | 122.47M | -36.16M | -29.53% |
| 2021 | 97.07M | -78.99M | -81.38% |
| 2022 | 86.16M | -121.75M | -141.31% |
| 2023 | 79.20M | -133.81M | -168.95% |
| 2024 | 67.63M | -116.04M | -171.58% |
ENTA Income Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 67.63M | 79.20M | 86.16M | 97.07M | 122.47M | 205.19M | 206.62M | 102.81M | 88.26M | 160.88M |
Cost of revenue | 0 | 0 | 2.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 67.63M | 79.20M | 83.18M | 97.07M | 122.47M | 205.19M | 206.62M | 102.81M | 88.26M | 160.88M |
Operating exp. | ||||||||||
Research and development | 131.47M | 163.52M | 164.52M | 174.11M | 136.75M | 142.21M | 94.85M | 57.45M | 40.46M | 23.18M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 189.32M | 216.41M | 210.00M | 206.64M | 164.11M | 168.45M | 118.29M | 78.2M | 57.42M | 36.73M |
Operating income | -121.69M | -137.20M | -123.84M | -109.57M | -41.63M | 36.73M | 88.32M | 24.61M | 30.84M | 124.14M |
Other income (expenses), net | 3.90M | 6.21M | 1.65M | 1.99M | 6.62M | 8.81M | 4.79M | 2.33M | 1.71M | 1.30M |
Income before tax | -117.78M | -130.99M | -122.18M | -107.57M | -35.01M | 45.55M | 93.12M | 26.94M | 32.56M | 125.45M |
Income tax expense | -1.74M | 2.82M | -433K | -28.58M | 1.14M | -826K | 21.16M | 9.23M | 10.89M | 46.46M |
Net income | -116.04M | -133.81M | -121.75M | -78.99M | -36.16M | 46.38M | 71.95M | 17.71M | 21.66M | 78.99M |
Earnings per share | ||||||||||
Basic EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 |
Diluted EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |